From discovery to the clinic: structural insights, engineering options, clinical, and 'next wave' applications of camelid-derived single-domain antibodies.

1 While most of the approved Ab-like therapeutics have the classical monospecific immunoglobulin G (IgG) composition, there is a clear trend toward more complex architectures, such as antibody-drug conjugates (ADCs) and bi- or multispecific antibodies. 3–7 In addition to this, chimeric antigen receptor (CAR) modified T cells, which are genetically engineered T cells expressing synthetic Ab-based paratopes as antigen-targeting receptors,

also in 19,460 other papers